HDL as a target in the treatment of atherosclerotic cardiovascular disease

Nature Reviews Drug Discovery

Volumn 4, Issue 3, 2005, Pages 193-205

  Linsel Nitschke, Patrick ^a   Tall, Alan R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DRF 272; ETC 216; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR STIMULATING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LIVER TRIACYLGLYCEROL LIPASE; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PRAVASTATIN; RAGAGLITAZAR; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANEMIA; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; EDEMA; FLUSHING; HEART INFARCTION; HUMAN; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; LEUKOPENIA; LIPID METABOLISM; LIVER DISEASE; META ANALYSIS; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RABBIT; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

ANIMALS; APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DRUG DELIVERY SYSTEMS; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RISK FACTORS;

EID: 14944381287     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1658     Document Type: Review

References (153)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
2. Sever, P. S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003).
3. Waters, D. D. et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 93, 154-158 (2004).
4. Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
5. Rhoads, G. G., Gulbrandsen, C. L. & Kagan, A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N. Engl. J. Med. 294, 293-198 (1976).
6. Genest, J. J., McNamara, J. R., Salem, D. N. & Schaefer, E. J. Prevalence of risk factors in man with premature coronary artery disease. Am. J. Cardiol. 67, 1185-1189 (1991).
7. Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418 (1999).
8. Frick, M. H. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987).
9. Assmann, G. & Schulte, H. The Prospective Cardiovascular Munster Study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am. J. Cardiol. 59, 9G-17G (1987).
10. Assmann, G. & Schulte, H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am. J. Cardiol. 70, 733-737 (1992).
11. Gordon, T., Kannel, W. B., Castelli, W. P. & Dawber, T. R. Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch. Intern. Med. 141, 1128-1131 (1981).
12. Williams, C. L. et al. Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 106, 143-160 (2002).
13. Bonow, R. O., Smaha, L. A., Smith, S. C., Mensah, G. A. & Lenfant, C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 106, 1602-1605 (2002).
14. Murray, C. J. & Lopez, A. D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349 1269-1276 (1997).
15. Brooks-Wilson, A. et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet. 22, 336-345 (1999).
16. Bodzioch, M. et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet. 22, 347-351 (1999).
17. Rust, S. et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet. 22, 352-355 (1999).
18. Costet, P., Luo, Y., Wang, N. & Tall, A. R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275, 28240-28245 (2000).
19. Sparrow, C. P. et al. A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J. Biol. Chem. 277, 10021-10027 (2002).
20. van Eck, M. et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl Acad. Sci. USA 99, 6298-6303 (2002).
21. Haghpassand, M., Bourassa, P. A., Francone, O. L. & Aiello, R. J. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. 108, 1315-1320 (2001).
22. Aiello, R. J. et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 22, 630-637 (2002).
23. Tan, J. H. et al. ABCA1 gone polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore. Hum. Genet. 113, 106-117 (2003).
24. Cohen, J. C. et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305, 869-872 (2004).
25. Frikke-Schmidt, R., Nordestgaard, B. G., Jensen, G. B. & Tybjaerg-Hansen, A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest. 114, 1343-1353 (2004).
26. Wang, N., Lan, D., Chen, W., Matsuura, F. & Tall, A. R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl Acad. Sci. USA 101, 9774-9779 (2004).
27. Zhang, W. et al. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 108, 2258-2263 (2003).
28. Rinninger, F. et al. Selective uptake of high-density, lipoprotein-associated cholesteryl esters by human hepatocytes in primary culture. Hepatology 19, 1100-1114 (1994).
29. Cockerill, G. W., Rye, K. A., Gamble, J. R., Vadas, M. A. & Barter, P. J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15, 1987-1994 (1995).
30. Baker, P. W., Rye, K. A., Gamble, J. R., Vadas, M. A. & Barter, P. J. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res. 40, 345-353 (1999).
31. Nissen, S. E. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300 (2003).
32. Uittenbogaard, A., Shaul, P. W., Yuhanna, I. S., Blair, A. & Smart, E. J. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 275, 11278-11283 (2000).
33. Yuhanna, I. S. et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nature Med. 7, 853-857 (2001).
34. Gong, M. et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J. Clin. Invest. 111, 1579-1587 (2003).
35. Nofer, J. R. et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113, 569-581 (2004).
36. Van Lenten, B. J., Navab, M., Shih, D., Fogelman, A. M. & Lusis, A. J. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med. 11, 155-161 (2001).
37. Nofer, J. R. et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1-16 (2002).
38. Vrecer, M., Turk, S., Drinovec, J. & Mrhar, A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J. Clin. Pharmacol. Ther. 41, 567-577 (2003).
39. Kockx, M., Princen, H. M. & Kooistra, T. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes - role of the peroxisome proliferator-activated receptor-α. Thromb. Haemost. 80, 942-948 (1998).
40. Neele, D. M., Kaptein, A., Huisman, H., de Wit, E. C. & Princen, H. M. No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased. Biochem. Biophys. Res. Commun. 244, 374-378 (1998).
41. Mardones, P. et al. Fibrates downregulate hepatic scavenger receptor class B type I protein expression in mice. J. Biol. Chem. 278, 7884-7890 (2003).
42. Robins, S. J. et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285, 1585-1591 (2001).
43. Frick, M. H. et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in man with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96, 2137-2143 (1997).
44. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102, 21-27 (2000).
45. Grundy, S. M., Mok, H. Y., Zech, L. & Berman, M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid Res. 22, 24-36 (1981).
46. Wise, A. et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278 9869-9874 (2003).
47. Rubic, T., Trottmann, M. & Lorenz, R. L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmarcol. 67, 411-419 (2004).
48. Etchason, J. A. et al. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin. Proc. 66, 23-28 (1991).
49. Clofibrate and niacin in coronary heart disease. JAMA 231, 360-381 (1975).
50. Carlson, L. A. & Rosenhamer, G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223, 405-418 (1988).
51. Brown, P. J. et al. Identification of a subtype selective human PPARα agonist through parallel-array synthesis. Bioorg. Med. Chem. Lett. 11, 1225-1227 (2001).
52. Miyachi, H. et al. Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators. Bioorg. Med. Chem. Lett. 12, 77-80 (2002).
53. Xu, Y.et al. Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor α agonist. J. Med. Chem. 46, 5121-5124 (2003).
54. Kuwabara, K. et al. A novel selective peroxisome proliferator-activated receptor α agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]-1, 3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. J. Pharmacol. Exp. Ther. 309, 970-977 (2004).
55. Spiegelman, B. M. & Flier, J. S. Obesity and the regulation of energy balance. Cell 104, 531-543 (2001).
56. Chinetti, G. et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med. 7, 53-58 (2001).
57. Akiyama, T. E. et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22, 2607-2619 (2002).
58. Claudel, T. et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl Acad. Sci. USA 98, 2610-2615 (2001).
59. Bavirti, S., Ghanaat, F. & Tayek, J. A. Peroxisome proliferator-activated receptor-γ agonist increases both low-density, lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control. Endocr. Pract. 9, 487-493 (2003).
60. Liang, C. P. et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J. Clin. Invest. 113, 764-773 (2004).
61. Vicent, D. et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 111, 1373-1380 (2003).
62. Li, A. C. et al. Differential inhibition of macrophage foam cell formation and atherosclerosis in mice by PPARα, β /δ and γ. J. Clin. Invest. 114, 1564-1576 (2004).
63. Berger, J. & Moller, D. E. The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435 (2002).
64. Moore, K. J., Fitzgerald, M. L. & Freeman, M. W. Peroxisome proliferator-activated receptors in macrophage biology: friend or foe? Curr. Opin. Lipidol. 12, 519-527 (2001).
65. Pasceri, V., Wu, H. D., Willerson, J. T. & Yeh, E. T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101, 235-238 (2000).
66. Lohray, B. B. et al. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy] phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. 44, 2675-2678 (2001).
67. Saad, M. F. et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 27, 1324-1329 (2004).
68. Skrumsager, B. K. et al. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR α and γ agonist in healthy subjects and patients with type 2 diabetes. J. Clin. Pharmacol. 43, 1244-1266 (2003).
69. Chakrabarti, R. et al. Ragaglitazar: a novel PPAR α PPAR γ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br. J. Pharmacol. 140, 527-537 (2003).
70. Larsen, P. J. et al. Differential influences of peroxisome proliferator-activated receptors gamma and-alpha on food intake and energy homeostasis. Diabetes 52, 2249-2259 (2003).
71. Ye, J. M. et al. PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am. J. Physiol. Endocrinol. Metab. 284, E531-E540 (2003).
72. Brand, C. L. et al. Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am. J. Physiol. Endocrinol. Metab. 284, E841-E854 (2003).
73. Peters, J. M. et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol. 20, 5119-5128 (2000).
74. Barak, Y. et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc. Natl Acad. Sci. USA 99, 303-308 (2002).
75. Wang, Y. X. et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113, 159-170 (2003).
76. Oliver, W. R. et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl Acad. Sci. USA 98, 5306-5311 (2001).
77. Vosper, H. et al. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J. Biol. Chem. 276, 44258-44265 (2001).
78. Brown, M. L. et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342, 448-451 (1989).
79. Inazu, A. et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238 (1990).
80. Bruce, C., Beamer, L. J. & Tall, A. R. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr. Opin. Struct. Biol. 8, 426-434 (1998).
81. Davidson, M. H. et al. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 169, 113-120 (2003).
82. Cho, K. H., Lee, J. Y., Choi, M. S., Bok, S. H. & Park, Y. B. Interaction of CETP inhibitory peptide and lipoprotein substrates in cholesteryl ester transfer assay: relationship between association properties and inhibitory activities. Lipids 37, 641-646 (2002).
83. de Grooth, G. J. et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105, 2159-2165 (2002).
84. Brousseau, M. E. et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505-1515 (2004).
85. Jiang, X. C. et al. Downregulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J. Blol. Chem. 268, 27406-27412 (1993).
86. Curb, J. D. et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. 45, 948-953 (2004).
87. Okamoto, H. et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203-207 (2000).
88. Morehouse, L. A., Sugarman, E. D., Bourassa, P. A. & A. J., M. HDL elevation by the CETP-inhibitor torcetrapib prevents aortic atherosclerosis in rabbits. Circulation (Suppl.) 110, III243 (2004).
89. Rittershaus, C. W. et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20 2106-2112 (2000).
90. Schaefer, E. J. et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am. J. Cardiol. 90, 689-696 (2002).
91. Gardner, C. D., Fortmann, S. P. & Krauss, R. M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276, 875-881 (1996).
92. Lamarche, B. et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95, 69-75 (1997).
93. Schaefer, E. J., Heaton, W. H., Wetzel, M. G. & Brewer, H. B. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2, 16-26 (1982).
94. Ng, D. S., Leiter, L. A., Vezina, C., Connelly, P. W. & Hegele, R. A. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J. Clin. Invest. 93, 223-229 (1994).
95. Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G. & Clift, S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353, 266-267 (1991).
96. Plump, A. S., Scott, C. J. & Breslow, J. L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl Acad. Sci. USA 91, 9607-9611 (1994).
97. Paszty, C., Maeda, N., Verstuyft, J. & Rubin, E. M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94, 899-903 (1994).
98. Liu, A. C., Lawn, R. M., Verstuyft, J. G. & Rubin, E. M. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J. Lipid Res. 35, 2263-2267 (1994).
99. Benoit, P. et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 99, 105-110 (1999).
100. Duverger, N. et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94, 713-717 (1996).
101. Miyazaki, A. et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 15 1882-1888 (1995).
102. Eriksson, M., Carlson, L. A., Miettinen, T. A. & Angelin, B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 100, 594-598 (1999).
103. Arakawa, R. & Yokoyama, S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J. Biol. Chem. 277, 22426-22429 (2002).
104. Wang, N. et al. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J. Clin. Invest. 111, 99-107 (2003).
105. Rader, D. J. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA 290, 2322-2324 (2003).
106. Llodra, J. et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl Acad. Sci. USA 101, 11779-11784 (2004).
107. Garber, D. W. et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42, 545-552 (2001).
108. Navab, M. et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105, 290-292 (2002).
109. Li, X. et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110, 1701-1705 (2004).
110. Jia, Z., Natarajan, P., Forte, T. M. & Bielicki, J. K. Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-I(Milano). Biochem. Biophys. Res. Commun. 297 206-213 (2002).
111. Bielicki, J. K. & Oda, M. N. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 41, 2089-2096 (2002).
112. Van Lenten, B. J. et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106, 1127-1132 (2002).
113. Van Lenten, B. J. et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 110, 3252-8 (2004).
114. Li, D. et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler. Thromb. Vasc. Biol. 19, 378-383 (1999).
115. Repa, J. J. & Mangelsdorf, D. J. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. 10, 557-563 (1999).
116. Chawla, A., Repa, J. J., Evans, R. M. & Mangelsdorf, D. J. Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001).
117. Annicotte, J. S., Schoonjans, K. & Auwerx, J. Expression of the liver X receptor α and β in embryonic and adult mice. Anat. Rec. 277A, 312-316 (2004).
118. Repa, J. J. et al. Regulation of mouse sterol regulatory element-binding protein-1 c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev. 14, 2819-2830 (2000).
119. Collins, J. L. et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45, 1963-1966 (2002).
120. Lund, E. G., Menke, J. G. & Sparrow, C. P. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 1169-1177 (2003).
121. Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604-7609 (2002).
122. Tangirala, R. K. et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl Acad. Sci. USA 99, 11896-11901 (2002).
123. Peet, D. J. et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93, 693-704 (1998).
124. Alberti, S. et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J. Clin. Invest. 107, 565-573 (2001).
125. Thomas, J. et al. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor α (PPARα) versus liver X receptor. J. Biol. Chem. 278, 2403-2410 (2003).
126. Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468 (2002).
127. Miao, B. et al. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 45, 1410-1417 (2004).
128. Costet, P. et al. Retinoic acid receptor-mediated induction of ABCA1 in macrophages. Mol. Cell. Biol. 23, 7756-7766 (2003).
129. McCoy, M. G. et al. Characterization of the lipolytic activity of endothelial lipase. J. Lipid Res. 43, 921-929 (2002).
130. Jaye, M. et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nature Genet. 21, 424-428 (1999).
131. Jin, W., Millar, J. S., Broedl, U., Glick, J. M. & Rader, D. J. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J. Clin. Invest. 111, 357-362 (2003).
132. Broedl, U. C. et al. Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. Circ. Res. 94, 1554-1561 (2004).
133. Ishida, T. et al. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E deficient mice. J. Biol. Chem. 279, 46085-45092 (2004).
134. Huang, Y. & Hall, I. H. Synthesis and pharmacological studies of 3-amino-2-methyl-1-phenyl-propanones as hypolipidemic agents in rodents. Arch. Pharm. (Weinheim) 329, 329-338 (1996).
135. Vieira-van Bruggen, D., Kalkman, I., van Gent, T., van Tol, A. & Jansen, H. Induction of adrenal scavenger receptor BI and increased high density lipoprotein-cholesteryl ether uptake by in vivo inhibition of hepatic lipase. J. Biol. Chem. 273, 32038-32041 (1998).
136. Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744 (2000).
137. Bishop-Bailey, D., Walsh, D. T. & Warner, T. D. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl Acad. Sci. USA 101, 3668-3673 (2004).
138. Willson, T. M., Jones, S. A., Moore, J. T. & Kliewer, S. A. Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med. Res. Rev. 21, 513-522 (2001).
139. Downes, M. et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11, 1079-1092 (2003).
140. Niesor, E. J., Flach, J., Lopes-Antoni, I., Perez, A. & Bentzen, C. L. The nuclear receptors FXR and LXRα: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr. Pharm. Des. 7, 231-259 (2001).
141. Kozarsky, K. F. et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 387, 414-417 (1997).
142. Ueda, Y. et al. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J. Biol. Chem. 275, 20368-20373 (2000).
143. Spady, D. K., Kearney, D. M. & Hobbs, H. H. Polyunsaturated fatty acids upregulate hepatic scavenger receptor B1 (SR-BI) expression and HDL cholesteryl ester uptake in the hamster. J. Lipid Res. 40, 1384-1394 (1999).
144. Wang, N., Weng, W., Breslow, J. L. & Tall, A. R. Scavenger receptor BI (SR-BI) is upregulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. J. Biol. Chem. 271, 21001-21004 (1996).
145. Levkau, B. et al. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 110, 3355-3359 (2004).
146. Kimura, T. et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23, 1283-1288 (2003).
147. Granata, R. et al. Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J. 18, 1456-1458 (2004).
148. Cohen, J. C., Wang, Z., Grundy, S. M., Stoesz, M. R. & Guerra, R. Variation at the hepatic lipase and apolipoprotein AI/CII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J. Clin. Invest. 94, 2377-2384 (1994).
149. Inazu, A. et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J. Clin. Invest. 94, 1872-1882 (1994).
150. Vu-Dac, N. et al. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. 273, 25713-25720 (1998).
151. Berthou, L. et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J. Clin. Invest. 97, 2408-2416 (1996).
152. Kennedy, M. A. et al. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276, 39438-39447 (2001).
153. Williams, K. J., Tall, A. R., Bisgaier, C. & Brocia, R. Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages. J. Clin. Invest. 79, 1466-1472 (1987).